Strategic partnerships Potential sales opportunity with Vaneltix leveraging their joint development agreement with Hyloris Pharmaceuticals to co-market or sublicense innovative non-oncological urology therapies, expanding reach into European markets.

Clinical leadership Engage with Vaneltix through physician leadership and clinical collaboration opportunities, given their appointment of a Chief Medical Officer and focus on Interstitial Cystitis/Bladder Pain Syndrome to position solutions in clinical practice.

Early-stage growth Vaneltix is a small, lean organization in the growth phase with a revenue range of roughly $1M-$10M, presenting an opportunity for targeted, high-value partnerships or distribution deals that can scale with their product candidates.

Urology market fit Capitalize on aging population trends and rising prevalence of IC/BPS by offering complementary products, devices, or services that enhance Vaneltix’s core therapeutic portfolio and expand non-oncological urology solutions.

Tech-enabled reach Leverage their lightweight tech stack and digital presence to deploy co-marketing, analytics partnerships, and customer engagement programs that accelerate product awareness and payer conversations in key regions.